|
Pure
Bioscience ~
$8,400,000 Common Stock
& Warrants ~
October 2007
PURE Biosciences patented new
antimicrobial molecule, silver dihydrogen citrate (SDC), is
stabilized ionic silver that can serve as a platform technology.
It is distinguishable from competitors in the marketplace
because of its superior efficacy, reduced toxicity and the
inability of bacteria to form a resistance to it. Currently used
as a powerful hard surface disinfectant, PURE is developing term
revenue opportunities for SDC as an active ingredient in other
products.
After leading a successful
offering for the Company last year, Taglich executed this larger
transaction of common stock with warrants at higher price levels
and valuation. Together, these two offerings provide PURE with
the necessary capital to fully advance its business strategy and
pursue the listing of its stock on a national exchange. Being
able to help clients as they grow is just another example of
Taglich Brothers’ commitment and support.
The information
contained herein does not constitute a solicitation of any order
to buy or sell any securities. The information provided herein
may be displayed and printed for your personal, noncommercial
use only. You may not reproduce, retransmit, distribute,
disseminate, sell, publish, broadcast or circulate the
information to anyone, without the express written consent of
Taglich Brothers, Inc.
|
